Clinical Trials
2 trialsNCT00385827 2014-08-20
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Centocor, Inc.
Phase 2 Terminated
NCT00401765 2014-05-26
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Centocor, Inc.
Phase 1 Completed